Skip to content

Arvinas ARVN Asset turnover

Asset turnover at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
0.1×0.0×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
0.0×
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
0.1×-0.4×
Immunome logo
ImmunomeIMNM
0.0×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
0.0×
Arcus Biosciences logo
Arcus BiosciencesRCUS
0.2×+0.1×

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on trailing twelve months.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's asset turnover?
Arvinas (ARVN) reported asset turnover of 0.1× in Q1 2026.
How has Arvinas's asset turnover changed year-over-year?
Arvinas's asset turnover decreased by 71.9% year-over-year, from 0.4× to 0.1×.
What is the long-term trend for Arvinas's asset turnover?
Over 4 years (2020 to 2025), Arvinas's asset turnover has grown at a 54.6% compound annual growth rate (CAGR), from 0.1× to 0.3×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.